Fulcrum Therapeutics (FULC) Leases (2022 - 2025)
Fulcrum Therapeutics (FULC) has disclosed Leases for 4 consecutive years, with $4.2 million as the latest value for Q4 2025.
- On a quarterly basis, Leases fell 25.39% to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 25.39% decrease, with the full-year FY2025 number at $4.2 million, down 25.39% from a year prior.
- Leases was $4.2 million for Q4 2025 at Fulcrum Therapeutics, down from $4.6 million in the prior quarter.
- In the past five years, Leases ranged from a high of $10.4 million in Q1 2022 to a low of $4.2 million in Q4 2025.
- A 4-year average of $7.2 million and a median of $6.9 million in 2023 define the central range for Leases.
- Peak YoY movement for Leases: decreased 17.17% in 2023, then dropped 25.39% in 2025.
- Fulcrum Therapeutics' Leases stood at $9.1 million in 2022, then fell by 20.82% to $7.2 million in 2023, then decreased by 20.79% to $5.7 million in 2024, then dropped by 25.39% to $4.2 million in 2025.
- Per Business Quant, the three most recent readings for FULC's Leases are $4.2 million (Q4 2025), $4.6 million (Q3 2025), and $5.0 million (Q2 2025).